Henry Schein (NASDAQ:HSIC) Given New $92.00 Price Target at Barrington Research

Henry Schein (NASDAQ:HSIC) had its target price upped by Barrington Research from $90.00 to $92.00 in a research report report published on Wednesday, Benzinga reports. They currently have an outperform rating on the stock. Barrington Research also issued estimates for Henry Schein’s Q2 2024 earnings at $1.27 EPS, Q3 2024 earnings at $1.31 EPS, Q4 2024 earnings at $1.42 EPS, FY2024 earnings at $5.10 EPS, Q1 2025 earnings at $1.14 EPS, Q2 2025 earnings at $1.34 EPS, Q3 2025 earnings at $1.39 EPS, Q4 2025 earnings at $1.59 EPS and FY2026 earnings at $6.00 EPS.

Several other brokerages have also weighed in on HSIC. UBS Group lowered their target price on shares of Henry Schein from $82.00 to $80.00 and set a neutral rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. increased their target price on Henry Schein from $82.00 to $88.00 and gave the stock an overweight rating in a research report on Wednesday, March 6th. Jefferies Financial Group raised their price target on Henry Schein from $74.00 to $81.00 and gave the stock a hold rating in a research note on Wednesday, March 6th. Piper Sandler upped their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the company an overweight rating in a research note on Monday, February 26th. Finally, TheStreet raised shares of Henry Schein from a c+ rating to a b- rating in a research report on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Henry Schein presently has a consensus rating of Hold and a consensus price target of $81.73.

Henry Schein Stock Up 1.2 %

Shares of NASDAQ:HSIC traded up $0.86 during trading on Wednesday, hitting $73.62. 170,296 shares of the company were exchanged, compared to its average volume of 1,097,360. The firm’s 50 day moving average price is $73.01 and its 200-day moving average price is $72.34. Henry Schein has a 12-month low of $60.01 and a 12-month high of $82.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. The stock has a market capitalization of $9.46 billion, a P/E ratio of 23.10, a PEG ratio of 1.68 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.21 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The business’s revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.21 EPS. On average, research analysts predict that Henry Schein will post 5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Henry Schein

In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at approximately $15,585,125.94. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Henry Schein

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Henry Schein by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 15,171,464 shares of the company’s stock worth $1,148,632,000 after purchasing an additional 161,891 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Henry Schein by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company’s stock valued at $353,898,000 after buying an additional 53,506 shares during the last quarter. American Century Companies Inc. raised its stake in Henry Schein by 7.3% during the third quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock valued at $350,392,000 after buying an additional 322,649 shares in the last quarter. Boston Partners lifted its holdings in Henry Schein by 144.1% during the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after buying an additional 1,556,831 shares during the last quarter. Finally, Fiduciary Management Inc. WI grew its position in shares of Henry Schein by 17.1% in the 4th quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock worth $172,947,000 after acquiring an additional 333,855 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.